The Latest Breaking News from RXRX

While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know.

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.